Double-blind, vehicle-controlled, single centre Phase I/IIa study with topical twice daily doses of 5% cis-urocanic acid to investigate pharmacokinetics, safety, tolerability, and efficacy for up to 28 days in subjects with mild to moderate plaque psoriasis.
Phase of Trial: Phase I/II
Latest Information Update: 19 Apr 2012
At a glance
- Drugs Urocanic acid (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 01 Aug 2011 New trial record